Prescription medicine
Caplacizumab Brand names: Cablivi
Caplacizumab (Cablivi) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the caplacizumab FDA label on DailyMed (effective April 24, 2026); every caplacizumab label on DailyMed.
Highlights of the record
FDA label of April 24, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageCABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Forms and strengths
Kit.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,709 through July 30, 2026
What is caplacizumab used for?
From the label: indications and usageCABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Source: FDA drug label (Cablivi), Genzyme Corporation, effective April 24, 2026 (SPL set 2348f06e-8004-4040-832e-e9e86a39f905), via openFDA; the full label on DailyMed
Is there a generic for caplacizumab (Cablivi)?
No generic caplacizumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the caplacizumab label say about other medicines?
The caplacizumab label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Heparin | drug interactions | Monitor closely for bleeding with concomitant use. ( 7 ) Concomitant Use of Anticoagulants, Thrombolytic Drugs, Heparin or Antiplatelet Agents Concomitant use of CABLIVI with any anticoagulant, thrombolytic drugs, heparin or antiplatelet agent may increase the risk of bleeding. |
Source: FDA drug label (Cablivi), Genzyme Corporation, effective April 24, 2026 (SPL set 2348f06e-8004-4040-832e-e9e86a39f905), via openFDA; the full label on DailyMed
What do FAERS reports show for caplacizumab?
The FDA Adverse Event Reporting System holds 1,709 reports that list caplacizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 105 are coded as a death and 347 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Caplacizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other